ClinicalTrials.gg
RecruitingNCT06140381Updated Nov 20, 2023

Strengthening in Sub-acute Stroke Survivors: A Randomized Controlled Trial

An interventional study of Eccentric training and Conventional therapy in Hemiparesis;Poststroke/CVA, sponsored by Clinique Du Parc de Belleville. Recruiting at 1 site in France. Open to participants aged 20 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-20.

Sponsored by Clinique Du Parc de Belleville · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 5 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Paresis with a site in France — 12 open to participants now, 12 under way, none of them phase 3. Paresis · France.

Planned enrollment
10th of 22
40 · median 40
Started
2023
with 3 others
No phase
22 of 26
9 open now
Primary completion
2024-06
later than 1 of 11 live
Registered
19th of 26
by date

Among the 26 studies in Paresis with a site in France, this one is the 10th largest by planned enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2023, is one of 22 with no phase, reaches primary completion later than 1 of the 11 other live ones, and was the 19th registered.

Paresis

473 studies on the registry are indexed under Paresis; 121 are open to participants now.

Browse Paresis studies →

Open to participants now

12 of the 26 studies in Paresis with a site in France are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 84 Paresis studies recruiting now, 34 (40%) set no upper age limit and 27 (32%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Paresis with a site in France, or all of them as a file.
02

Study summary

The goal of this study is to compare between Eccentric training and conventional therapy in sub-acute stroke survivors. The primary objective of this study is to evaluate improvements in gait speed after four months of ET in comparison to conventional therapy for patients with sub-acute stroke. Secondary objectives involve assessing: i) modifications in neuromuscular parameters of PF, ii) changes in muscle stiffness within PF during passive mobilization and active force generation, and iii) modifications in architectural parameters of PF.

Read the detailed description

This study will be a single-blinded, controlled, randomized design, wherein participants will be randomly assigned to one of two groups: the Conventional Therapy Group (CTG) or the Eccentric Training Group (ETG). Both groups will undergo a comprehensive series of assessments at three key time points: Ji (initial assessment), Jint (intermediate assessment), and Jf (final assessment). The study will commence with a recruitment phase, followed by a screening phase. Subsequently, there will be a 4-week period allocated for experimental testing before the intervention, and an additional 4 weeks for experimental testing after the intervention. These assessments will encompass a wide range of evaluations, including clinical health assessments, biomechanical assessments, neuromuscular evaluations, and functional assessments

03

Conditions studied

  • Hemiparesis;Poststroke/CVA

Browse trials for

Keywords

  • Rehabilitation
  • Skeletal muscle
  • Eccentric strengthening
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subacute hemiparesis (> 3 months)
  • between 18.5 and 25
  • Written consent to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Ankle impairment
  • Botulinum toxin injections in PF within the last 4 months before study inclusion
  • Medical for maximal effort
  • Neurodegenerative disorders
  • Cardiovascular disorders
  • History of epilepsy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    CTG

    In conventional therapy, the treatment plan is determined based on medical opinion. After admission, each patient undergoes several multidisciplinary assessments aimed at objectively determining the care based on their needs. In this group, patients received only conventional rehabilitation. This will carry out in the same manner as a regular practice of the clinic. 3 sessions per week

    Procedure: Conventional therapy

  • Experimental
    ETG

    In the absence of a standardized eccentric isokinetic training protocol established for hemiparetic subjects on the plantar flexor muscles, the protocol designed for this study drew inspiration from the one established by Clark and Patten. (2013) and by Harris-Love et al. (2017).This protocol allows the introduction of an eccentric stimulus for individuals who are new to this type of training and progressively advances their program to include workload levels sufficiently to stimulate muscle plasticity optimally, thereby inducing skeletal muscle adaptations. 3 sessions per week

    Procedure: Eccentric training · Procedure: Conventional therapy

Interventions

  • ProcedureEccentric training

    The eccentric program will last for 16 weeks, with a frequency of 2 sessions per week, totalling 32 sessions. At least 1 day of rest will be required between two training sessions. The participants will be placed in the similar position of the neuromuscular assessments (reference position). The Biodex System 4 dynamometer settings for the exercise sessions were also like the settings used for the assessments. The training program will be divided into two phases: a familiarization phase and a progression phase

  • ProcedureConventional therapy

    3 sessions per week of physical therapy with musculotendinous stretching and balance rehabilitation

06

What researchers measure

Primary outcomes

  1. gait speed (m/s) through the 10-meter walking test.

    An analysis of the walking pattern will be conducted to quantify the evolution of spatio-temporal and barometric parameters of walking and their asymmetry.

    Time frame: initial assessment in the first week of the inclusion, intermediate assessment at 6 weeks of the inclusion, and final assessment at 12 weeks of the inclusion

Secondary outcomes

  1. Biomechanical proprieties

    muscle stiffness, as expressed by the shear modulus (µ, in Kpa), will be assessed during passive ankle joint mobilization from dorsiflexion to plantar flexion and during maximal voluntary isometric contraction of Plantar flexors

    Time frame: initial assessment in the first week of the inclusion, intermediate assessment at 6 weeks of the inclusion, and final assessment at 12 weeks of the inclusion

  2. Structural parameters

    Fascicle length and thickness (mm) will be assessed using the ultrasound scanner.

    Time frame: initial assessment in the first week of the inclusion, intermediate assessment at 6 weeks of the inclusion, and final assessment at 12 weeks of the inclusion

  3. Neuromuscular parameters

    Peak force (N/m), submaximal force (N/m) and rate of force development (N/m) will be evaluated using the BIODEX isokinetic device during maximal volontary contraction

    Time frame: initial assessment in the first week of the inclusion, intermediate assessment at 6 weeks of the inclusion, and final assessment at 12 weeks of the inclusion

  4. Functional parameters

    maximal range of motion (deg/s) , defined as the extent of stretch that the participant can comfortably endure during the stretching maneuver, will be measured using the BIODEX isokinetic device

    Time frame: initial assessment in the first week of the inclusion, intermediate assessment at 6 weeks of the inclusion, and final assessment at 12 weeks of the inclusion

07

Study locations

1 of 1 sites recruiting
  • Wael Maktouf
    Créteil, 94000, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Data will be shared upon request from researchers

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2023; primary completion for Jun 2024, 6 months later.

Of 223 non-industry interventional studies with no phase under Paresis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 55. This study's planned 6 months is below that.

Counting every sponsor, half of 241 studies reached it within 32 months; a quarter within 13 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2023
First posted
Nov 20, 2023
StartEst.
Dec 1, 2023
Primary completionEst.
Jun 1, 2024
CompletionEst.
Oct 1, 2024
Last update
Nov 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06140381
Lead sponsor
Clinique Du Parc de Belleville
Collaborators
Henri Mondor University Hospital
Responsible party
Belghith Kalthoum (Principal investigator, Clinique Du Parc de Belleville) — Principal investigator
First posted
Nov 20, 2023
Start date
Dec 1, 2023 (estimated)
Primary completion
Jun 1, 2024 (estimated)
Completion
Oct 1, 2024 (estimated)
Last update
Nov 20, 2023

Study contacts

belghith kalthoum, Investigator
Contact
belghith.kalthoum@gmail.com
0649260709
Rayan Bouserhal, Investigator
Contact
resp-reeducation.belleville@orpea.net
0171939300
Fedele Jean Michel, Investigator
principal investigator · Clinique Du Parc de Belleville

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion